BEAM

Beam Therapeutics Inc.

Investor Moves

InvestorPortfolio ValuePortfolio ChangePosition ChangeAvg Buy PriceCurrent Price
Cathie WoodARK Invest
$289M12.1M shares
TrimQ1 2026
$56M
$23.83
$31.89

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Cooper Graham KDirector
--19.7k shares
Grant / ExerciseJun 3, 2026
$581.4K19.7k shares
$29.55
$31.89
Guindo ChirfiDirector
--19.7k shares
Grant / ExerciseJun 3, 2026
$581.4K19.7k shares
$29.55
$31.89
Fishman MarkDirector
--19.7k shares
Grant / ExerciseJun 3, 2026
$581.4K19.7k shares
$29.55
$31.89
Maraganore JohnDirector
--19.7k shares
Grant / ExerciseJun 3, 2026
$581.4K19.7k shares
$29.55
$31.89
Walsh Kathleen EDirector
--19.7k shares
Grant / ExerciseJun 3, 2026
$581.4K19.7k shares
$29.55
$31.89
Shaw ChristiDirector
--19.7k shares
Grant / ExerciseJun 3, 2026
$581.4K19.7k shares
$29.55
$31.89

News

zacks.com3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026zacks.comJun 2seekingalpha.comBeam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 25marketbeat.comBeam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advancesmarketbeat.comMay 20globenewswire.comBeam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conferenceglobenewswire.comMay 18fool.comHedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?fool.comMay 18